Entrada Therapeutics, Inc.
TRDANASDAQHealthcare● Active
$6.26
$-0.11(-1.73%)
Market Cap$243017056
P/E Ratio—
52W High$16.45
52W Low$4.93
Entrada Therapeutics, Inc. (TRDA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TRDA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.95
Est. -$1.06 · +10.4%
Revenue
$0.00B
Est. $0.00B · -70.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
TRDA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$1.06 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$1.06 | -$0.95 | +10.4% | $0.00B | $0.00B | -70.0% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$1.32 | -$0.94 | +28.8% | $0.00B | $0.01B | -82.5% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$1.04 | -$1.06 | -1.9% | $0.00B | $0.01B | -81.0% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$0.86 | -$1.04 | -20.9% | $0.00B | $0.01B | -75.1% |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.78 | -$0.42 | +46.1% | $0.02B | $0.01B | +110.4% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.66 | $0.03 | +104.5% | $0.04B | $0.01B | +185.0% |
| ▲ Q4 FY2024 | Nov 5, 2024 | -$0.67 | -$0.35 | +47.8% | $0.02B | $0.01B | +51.4% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$1.06
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.95
EPS Est.
-$1.06
EPS Surpr.
+10.4%
Revenue
$0.00B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.94
EPS Est.
-$1.32
EPS Surpr.
+28.8%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$1.06
EPS Est.
-$1.04
EPS Surpr.
-1.9%
Revenue
$0.00B
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$1.04
EPS Est.
-$0.86
EPS Surpr.
-20.9%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.42
EPS Est.
-$0.78
EPS Surpr.
+46.1%
Revenue
$0.02B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
$0.03
EPS Est.
-$0.66
EPS Surpr.
+104.5%
Revenue
$0.04B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
-$0.35
EPS Est.
-$0.67
EPS Surpr.
+47.8%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $-1.72 | $-0.60 | $0.11 | 1 |
| Q3 FY2030 | $-1.72 | $-0.60 | $0.11 | 1 |
| Q2 FY2030 | $-0.04 | $0.20 | $0.57 | 1 |
| Q1 FY2030 | $-1.72 | $-0.60 | $0.11 | 1 |
| Q4 FY2029 | $-2.29 | $-0.80 | $0.15 | 1 |
| Q3 FY2029 | $-2.29 | $-0.80 | $0.15 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2030 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2030 | $0.0B | $0.1B | $0.2B | 2 |
| Q1 FY2030 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +10.4% | $16.03 | $6.85 | -57.27% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +28.8% | $11.98 | $12.79 | +6.76% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -1.9% | $6.94 | $6.95 | +0.14% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -20.9% | $5.83 | $5.95 | +2.06% |
| ▲ Q2 FY2025 | May 8, 2025 | +46.1% | $8.16 | $8.62 | +5.64% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +104.5% | $12.02 | $11.98 | -0.33% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +47.8% | $17.77 | $18.62 | +4.78% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +1007.1% | $14.21 | $15.81 | +11.26% |
Q2 FY2026-57.27%
Report Date
May 7, 2026
EPS Beat/Miss
+10.4%
Price Before
$16.03
Price After
$6.85
Q1 FY2026+6.76%
Report Date
Feb 26, 2026
EPS Beat/Miss
+28.8%
Price Before
$11.98
Price After
$12.79
Q4 FY2025+0.14%
Report Date
Nov 6, 2025
EPS Beat/Miss
-1.9%
Price Before
$6.94
Price After
$6.95
Q3 FY2025+2.06%
Report Date
Aug 6, 2025
EPS Beat/Miss
-20.9%
Price Before
$5.83
Price After
$5.95
Q2 FY2025+5.64%
Report Date
May 8, 2025
EPS Beat/Miss
+46.1%
Price Before
$8.16
Price After
$8.62
Q1 FY2025-0.33%
Report Date
Feb 27, 2025
EPS Beat/Miss
+104.5%
Price Before
$12.02
Price After
$11.98
Q4 FY2024+4.78%
Report Date
Nov 5, 2024
EPS Beat/Miss
+47.8%
Price Before
$17.77
Price After
$18.62
Q3 FY2024+11.26%
Report Date
Aug 13, 2024
EPS Beat/Miss
+1007.1%
Price Before
$14.21
Price After
$15.81
Avg Beat Reaction-4.86%
Avg Miss Reaction+1.10%
Beat Rate6 / 8 quarters
Largest Move-57.27% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TRDA ends December
Entrada Therapeutics, Inc. (TRDA) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.95 — beating the analyst consensus of $-1.06 by +10.4%. TRDA has beaten EPS estimates for 2 consecutive quarters. The next TRDA earnings date is expected around September 1, 2026.
Each quarter, investors track TRDA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TRDA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TRDA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TRDA earnings · 5 questionsEntrada Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. TRDA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TRDA historically reports after market close (AMC).
TRDA earnings datewhen is TRDA earningsTRDA next earnings datewhen does TRDA report earningsTRDA earnings calendar
▸ Source: FMP · Entrada Therapeutics, Inc. SEC filings · US GAAP · Entrada Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026